A rumor also brought a faucet with eye -catching medicine, and Xingqi's eye medicine plummeted 16%, and the market value was not 2.4 billion.

Following the crash of Goor's shares, the eye medicine of the ophthalmology was also criticized.

On the morning of June 24th, Xingqi's eyebrows crashed. As of the closing stock price, the stock price fell 16.76%to 136.02 yuan/share, and the market value evaporated 2.4 billion yuan to 12 billion yuan.

According to market rumors, the company may be affected by rumors of Internet hospitals to restrict the rumor of Atropine. In response, the city industry called the director to verify that the passage of the pass has not been connected.

As a rejuvenating eye medicine focusing on the field of ophthalmology, its main products are ophthalmology prescriptions. The revenue is mainly composed of three major sections of gel agents/eye paste, eye drops, and solution agents. The first two major sections account for more than 60 %, including anti -infection drugs, anti -inflammatory/anti -infection drugs, and ducts. Medicine and ciliary muscle paralysis, non -steroid anti -inflammatory drugs, pupil shrinkage drugs and antimicolital eye drugs.

The protagonist of this incident, Atto, is mainly used to control adolescent myopia. It is a heavy product for Xingqi eye medicine, and it is also an important pillar that constitutes the income of eye drops. According to a report from the US Science Authoritative Magazine in 2016, the most effective means among 16 children's myopia prevention and control methods are ophthalmic drugs including "Atto", followed by OK mirror (corneal shaping mirror), and finally It's glasses. However, whether it is 0.01%Atropine or 0.05%of Atto, it cannot be treated with myopia. This medicine is a prescription medicine. Before use Happening.

In 2018, Xingqi Eye Medicine became the earliest batch of Atropine R & D enterprises to enter the clinical stage. Sales Atto. The so -called intra -hospital preparation refers to the fixed prescription preparation of medical institutions based on clinical needs and approval.

This not only opened the sales of Xingqi eye medicine, but also became an important reason for its stock price. In the first quarter of 2021 and 2022, the revenue of Eye medicine was 10.28 to 3.02 billion yuan, and net profit reached 1.95 to 1.074 billion yuan, an increase of 121.31%and 123.36%year -on -year. Its stock price has skyrocketed from the listing price of 5.16 yuan in 2016. On July 23, 2020, the highest point was 225.7 yuan/share, which increased by 4293%from the issue price.

In January of this year, the survey released by "Daily Economic News" reported "A myopia" Shen Dao "to support ten times the shares: Xingqi Eye Bulletin bypass the Internet Harvesting and Unfered Obcentrics" stated that Xingqi Eye Medicine Pharmaceuticals Pharmaceuticals Pharmaceuticals The low -concentration Atto eye drops that control adolescent myopia have not been officially approved for listing, but it has been sold through the Xingqi Ophthalmology Hospital with an Internet hospital.

The city boundary found that theoretically, it can only be purchased by the prescriptions of Xingqi Eye Hospital to buy Atropine Drops. At present, it is also sold on some e -commerce platforms. The banner of eye drops.

It is worth mentioning that in the 2021 annual report, the three projects that involved the delay of children's myopia were still in the phase III clinical trial stage.

(Author ｜ Zeng Jiayi, Editor | Liao Ying)

- END -